Gismo Therapeutics Inc. is developing novel disease modifying, first in class small molecule therapeutics for the treatment of Alzheimer’s and Parkinson’s Disease. The company was founded on breakthrough science in the field of Glycosaminoglycan (GAG) – Interacting Small Molecules (GISMO), a technology invented by the company’s founder, Paul Gregor, and associated with a new hypothesis of the etiology of major neurodegenerative diseases. The company is privately held, funded by private investors and grant awards. The company was awarded in 2013 a SBIR grant from NIH to develop novel therapeutics from Alzheimer’s Disease, and in 2014 is a recipient of a Michael J. Fox Foundation for Parkinson’s Disease grant. The company is incorporated in Delaware and has offices in Lexington, Kentucky and Queens, New York.


Today, more than 5 million Americans are suffering from Alzheimer’s disease. The disease ravages the minds of patients, crushes entire families and currently costs the health care system $200 billion a year. These sobering statistics are projected to get much worse as the 76 million American baby boomers age. Hope for the future lies in medical innovation. Industry analysts predict a single new and truly effective AD drug could capture annual sales of over $10 billion.


UKY_VAICollaborations and partnering are key aspects of the company’s strategy. GISMO Inc. is collaborating in the field of AD and PD with top academic groups at the University of Kentucky, Lexington, KY and the Van Andel Research Institute in Grand Rapids, MI.